CD22 (Epratuzumab Biosimilar) 抗体
(CD22 (Epratuzumab Biosimilar))
Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins\; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.
antibodies-online.com stands for high-quality research products. Search, find and order tools with extensive validation data, images, references. Our scientific customer service is always at your disposal if you have any questions about the selection or application of our products.
Recommended CD22 (Epratuzumab Biosimilar) 抗体
Product
Reactivity
Application
Validations
Cat. No.
Quantity
Datasheet
Reactivity
Cynomolgus, Human, Rhesus Monkey
Application
BP, FACS, IP
Validations
- (3)
Cat. No.
ABIN5668217
Quantity
200 μg
Datasheet
Datasheet
Reactivity
Cynomolgus, Human, Rhesus Monkey
Application
BP, FACS, IP
Validations
Cat. No.
ABIN5668216
Quantity
200 μg
Datasheet
Datasheet
Synonyms and alternative names related to CD22 (Epratuzumab Biosimilar)
CD22 molecule (CD22), SIGLEC-2, SIGLEC2Protein level used designations for CD22 (Epratuzumab Biosimilar)
- B-cell receptor CD22
- B-lymphocyte cell adhesion molecule
- BL-CAM
- CD22 antigen
- T-cell surface antigen Leu-14
- sialic acid binding Ig-like lectin 2
- sialic acid-binding Ig-like lectin 2
You are here:
